Loading...
•
Dec 31, 2024
Supernus Q4 2024 Earnings Report
Supernus Pharmaceuticals, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting significant growth in Qelbree and GOCOVRI sales, improved operating earnings, and the FDA approval of ONAPGO.
Key Takeaways
Supernus Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by substantial increases in Qelbree and GOCOVRI net product sales. Total revenues for Q4 2024 reached $174.2 million, with operating earnings of $21.4 million and diluted EPS of $0.27. The company also announced the FDA approval of ONAPGO, with a planned launch in Q2 2025.
Fourth quarter 2024 net sales of Qelbree increased 60% to $74.4 million, compared to the same period in 2023.
Fourth quarter 2024 net sales of GOCOVRI increased 15% to $36.9 million, compared to the same period in 2023.
Operating earnings for the fourth quarter of 2024 were $21.4 million, a significant improvement from an operating loss of $(1.0) million in the same period in 2023.
ONAPGO (apomorphine hydrochloride) was approved by the U.S. Food and Drug Administration and is set to launch in the second quarter of 2025.
Revenue by Segment
Forward Guidance
For the full year 2025, Supernus Pharmaceuticals expects total revenues to be between $600 million and $630 million, with operating earnings (loss) ranging from $(15) million to $10 million, and adjusted operating earnings (non-GAAP) between $105 million and $130 million.
Positive Outlook
- Continued Qelbree growth is expected.
- Launch of ONAPGO for Parkinson's disease is planned for the second quarter of 2025.
- Further advancement of the product pipeline.
- Adjusted operating earnings (non-GAAP) are projected to be positive, ranging from $105 million to $130 million.
- The company anticipates generating cash from operations.
Challenges Ahead
- Total revenues are projected to decrease compared to FY 2024.
- Operating earnings are projected to be a loss, ranging from $(15) million to $10 million.
- Continued generic erosion of Trokendi XR is expected.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...